pbs_code string | drug string | brand string | formulation string | indication string | treatment_phase string | streamlined_code string | online_application bool | authority_method string | hospital_type string | schedule_code int64 | schedule_year int64 | schedule_month string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
10056G | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10056G | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10056G | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10056G | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10058J | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10058J | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10058J | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10058J | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10058J | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10058J | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10060L | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10060L | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10060L | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10060L | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10064Q | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10064Q | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10064Q | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10064Q | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10068X | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10068X | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10068X | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10068X | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10071C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10071C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10071C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10071C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10071C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10071C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10072D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10072D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10072D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10072D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10072D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10072D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10073E | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10073E | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10073E | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10073E | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10073E | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10073E | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10077J | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10077J | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10077J | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10077J | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10078K | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10078K | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10078K | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10078K | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10078K | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10078K | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10079L | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10079L | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10079L | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10079L | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,834 | 2,025 | NOVEMBER |
10081N | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10081N | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10081N | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10081N | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10081N | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10081N | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,834 | 2,025 | NOVEMBER |
10137M | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10137M | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10238W | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10238W | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10511F | Tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10511F | Tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10517M | Tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10517M | Tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10517M | Tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10517M | Tofacitinib | Xeljanz | Tablet 5 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10767Q | Ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10767Q | Ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | First continuing, Subsequent continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10767Q | Ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10774C | Ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10774C | Ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10774C | Ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10774C | Ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10890E | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10890E | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10890E | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10892G | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10893H | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10894J | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10894J | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10894J | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10895K | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10895K | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10896L | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10897M | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10898N | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10899P | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10899P | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10900Q | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10900Q | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10900Q | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10901R | Secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10904X | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10904X | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10904X | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
10905Y | Certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,834 | 2,025 | NOVEMBER |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 14